Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO(R) (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback